Skip to content

PEAK PHARMACEUTICALS, INC.: 10-Q filed 2022-12-19

What PEAK PHARMACEUTICALS, INC. reported in its quarterly report filed 2022-12-19 (fiscal Q3 2018): 18 published measures, 55 facts as tagged in accession 0001199835-22-000812.

This filing

Form
10-Q (quarterly report)
Filed
2022-12-19
Fiscal period
fiscal Q3 2018
Accession
0001199835-22-000812 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PEAK PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-06-30558USD
At 2018-09-302,270USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-06-30231,805USD
At 2018-09-30223,362USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-06-30-231,247USD
At 2019-03-31-227,588USD
At 2018-12-31-223,951USD
At 2018-09-30-221,092USD
At 2018-06-30-213,987USD
At 2018-03-31-209,703USD
At 2017-12-31-200,314USD
At 2017-09-30-192,685USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-3,659USD91
2018-10-01 to 2019-06-30-10,155USD273
2019-01-01 to 2019-03-31-3,637USD90
2018-10-01 to 2018-12-31-2,859USD92
2018-04-01 to 2018-06-30-4,284USD91
2017-10-01 to 2018-06-30-21,302USD273
2018-01-01 to 2018-03-31-9,389USD90
2017-10-01 to 2017-12-31-7,629USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-10-01 to 2019-06-30-1,712USD273
2017-10-01 to 2018-06-30-28,632USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-10-01 to 2018-06-3043,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-06-30-5,094,649USD
At 2018-09-30-5,084,494USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-1,483USD91
2018-10-01 to 2019-06-30-4,209USD273
2018-04-01 to 2018-06-30-2,998USD91
2017-10-01 to 2018-06-30-18,208USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-06-30558USD
At 2018-09-302,270USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-04-01 to 2019-06-302,176USD91
2018-10-01 to 2019-06-305,946USD273
2018-04-01 to 2018-06-301,286USD91
2017-10-01 to 2018-06-303,094USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-06-30231,805USD
At 2018-09-30223,362USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-06-30155,672USD
At 2018-09-30153,176USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-04-01 to 2019-06-301,483USD91
2018-10-01 to 2019-06-304,209USD273
2018-04-01 to 2018-06-302,998USD91
2017-10-01 to 2018-06-3018,208USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-06-3078,363,567shares
At 2018-09-3078,363,567shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-06-304,855,566USD
At 2018-09-304,855,566USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-06-3013,133USD
At 2018-09-307,186USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-301,483USD91
2018-10-01 to 2019-06-304,209USD273
2018-04-01 to 2018-06-302,998USD91
2017-10-01 to 2018-06-3018,208USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2018-10-01 to 2019-06-30-2,517USD273
2017-10-01 to 2018-06-30-365USD273

Inspect the source

Entity
PEAK PHARMACEUTICALS, INC. / CIK 0001452804
Captured
2026-09-20T09:05:40.595Z
SEC response SHA-256
3fd5eb06bfdebffa42021b094c4c379c1efd3c7143204265bf035090db070211

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001452804.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))